Obsidian Therapeutics OBX-115 Phase 2 Melanoma Data to Be Presented at ASCO 2026

Key Takeaways

• Obsidian Therapeutics will present Phase 2 clinical data for OBX-115 in advanced melanoma patients at the 2026 ASCO Annual Meeting
• OBX-115 is an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy targeting melanoma that has progressed after checkpoint inhibitor treatment
• The oral presentation will feature results from the Agni-01 multicenter study, marking a significant milestone for this novel immunotherapy approach

---

Obsidian Therapeutics announced it will deliver an oral presentation of Phase 2 clinical trial results for OBX-115 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation will focus on patients with advanced melanoma who experienced disease progression following immune checkpoint inhibitor therapy.

Novel TIL Cell Therapy Approach

OBX-115 represents a next-generation approach to cancer immunotherapy as an engineered, autologous tumor-infiltrating lymphocyte (TIL) cell therapy. The treatment involves extracting immune cells from a patient’s own tumor, engineering them to enhance their cancer-fighting capabilities, and reinfusing them back into the patient.

The data being presented comes from the Agni-01 multicenter study, a Phase 1/2 clinical trial evaluating OBX-115’s safety and efficacy in patients with advanced melanoma. This patient population represents a significant unmet medical need, as treatment options become limited after checkpoint inhibitor failure.

Expanding Clinical Development

Beyond the Phase 2 melanoma trial, Obsidian Therapeutics is also conducting a Phase 1 clinical trial of OBX-115, indicating the company’s commitment to advancing this therapeutic approach across multiple development pathways.

The ASCO presentation represents a critical milestone for Obsidian Therapeutics, as oral presentations at the world’s premier oncology conference are reserved for the most significant clinical advances. The selection suggests that OBX-115 may have demonstrated meaningful clinical activity in this challenging patient population.

Market Implications

The advanced melanoma treatment landscape has been transformed by checkpoint inhibitors, but patients who progress on these therapies face limited options. TIL cell therapies like OBX-115 offer a promising alternative approach by harnessing and enhancing the patient’s own immune system to fight cancer.

The 2026 ASCO presentation will provide the medical community with crucial insights into OBX-115’s potential role in treating checkpoint inhibitor-refractory melanoma, potentially positioning it as a new standard of care option for this patient population.

---

Frequently Asked Questions

What is OBX-115 and how does it work?

OBX-115 is an engineered autologous TIL (tumor-infiltrating lymphocyte) cell therapy that uses a patient’s own immune cells, extracted from their tumor, engineered to enhance cancer-fighting capabilities, and reinfused to treat advanced melanoma.

When will OBX-115 be available to patients?

OBX-115 is currently in Phase 2 clinical trials for melanoma and Phase 1 trials for other indications. The therapy is not yet approved and availability will depend on successful completion of clinical trials and regulatory approval, which typically takes several years.

How does OBX-115 compare to existing melanoma treatments?

OBX-115 targets patients whose melanoma has progressed after checkpoint inhibitor therapy, addressing an unmet medical need. Unlike standard treatments, it uses engineered autologous immune cells, potentially offering a personalized approach for patients with limited treatment options.